Wilson Sonsini Goodrich & Rosati
Firm overview:
Widely recognised as a formidable competitor in patent work, Wilson Sonsini Goodrich & Rosati continues to strengthen its profile across both the life sciences and technology sectors. The firm’s bench of more than 170 patent and IP practitioners is heavily weighted toward scientific expertise, with advanced degrees in biology, chemistry, biomedical sciences and related fields, giving it an advantage in highly technical disputes and advisory work.
The firm also maintains a strong presence in cutting-edge technology areas, including artificial intelligence (AI) and machine learning, having advised hundreds of AI-focused companies on strategic IP matters.
In 2025, Wilson Sonsini’s life sciences IP credentials were underscored when the firm was named Life Sciences IP Firm of the Year at the Life Sciences Patent Network (LSPN) Awards USA, organised by WIPR sister title LSIPR, an accolade recognising excellence in pharmaceutical and biotech patent protection. It was also a finalist in multiple related categories, including strategy and litigation.
Team overview:
At the forefront of Wilson Sonsini’s patent litigation efforts is San Francisco-based co-chair Wendy Devine, who leads complex disputes with a particular emphasis on Hatch-Waxman litigation and pharmaceutical patent strategy. Devine’s scientific background informs her strategic counsel to life sciences companies navigating challenging IP landscapes.
Within the broader IP practice, Wilson Sonsini continues to cultivate talent, electing new partners with expertise across litigation and innovation disciplines as part of its 2025 and 2026 partner classes, including attorneys specialising in patents and innovation strategy.
Key matters:
- PTAB proceedings for Azurity Pharmaceuticals
Wilson Sonsini secured a noteworthy Patent Trial and Appeal Board milestone in late 2025 when the PTAB instituted inter partes review proceedings on all five petitions filed on behalf of Azurity Pharmaceuticals, targeting methods and compositions for treating chemotherapy-induced nausea and vomiting.
The Board’s institution decisions found a reasonable likelihood that Azurity will prevail on at least one challenged claim in each proceeding—significant in the context of the current PTAB environment, where institution rates have tightened.
The Wilson Sonsini team representing Azurity includes Richard Torczon, Jad Mills, Wendy Devine, Michael Rosato, Natalie Morgan, Garrett Potter, and Patrick Medley.
Clients:
Azurity Pharmaceuticals
